RenovoRx (RNXT) announced that it is increasing production of its FDA-cleared RenovoCath catheter-based device in order to meet increased demand for the targeted delivery of diagnostic and/or therapeutic agents from oncologists and interventional radiologists. The principal manufacturer of RenovoCath devices is Medical Murray Inc., based in the U.S. in North Barrington, Illinois.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx: Promising Phase 3 Study and Revenue Growth Drive Buy Rating
- RenovoRx Delays Yearly Report Filing
- RenovoRx’s Innovative Approach to Pancreatic Cancer Treatment: A Promising Investment Opportunity
- RenovoRx initiated with a Buy at H.C. Wainwright
- RenovoRx advnaces RenovoCath commercialization